Poster Session I - ACUTE ISCHEMIC STROKE MANAGEMENT 01.00 - ACUTE ISCHEMIC STROKE MANAGEMENT - 01.05 - NEUROINTERVENTION P083 - ESOC25-231 COMORBIDITY BURDEN AND OUTCOMES AFTER ENDOVASCULAR THROMBECTOMY FOR MEDIUM VESSEL OCCLUSIONS Emma Hall 1 , Johan Wasselius 1 , Mats Pihlsgrd 2 , Teresa Ullberg 3 , Bjrn Hansen 1 1 Diagnostic Radiology, Department of Clinical Science, Lund, Sweden, 2 Perinatal and Cardiovascular Epidemiology, Department of Clinical Science, Malm, Sweden, 3 Department of Neurology, Department of Clinical Science, Malm, Sweden Background and Aims: Patients with severe comorbidities are underrepresented in the ongoing randomized endovascular thrombectomy (EVT) trials for medium vessel occlusions (MeVOs)
In the CY 2026 OPPS/ASC proposed rule (90 FR 33766), for the CY 2027 reporting period, we proposed that hospitals that voluntarily submit Emergency Care Access & Timeliness eCQM data could submit data for any quarter(s) (that is, up to all four quarters of data)
Promotion of immune and repair cell mobility through influence on the actin cytoskeleton
Urolithin A prevents focal cerebral ischemic injury via attenuating apoptosis and neuroinflammation in mice
The honest answer is that the evidence cannot say, because no study has ever compared them directly in the same model, let alone in humans
Some examples include: Increased Fat Burning: The peptides CJC-1295 + Ipamorelin encourage the production of growth hormone which can lead to the breakdown of stored fat for energy
/assets/images/provider/photos/2749086.jpeg)
